source
- Capricor Therapeutics receives second FDA rejection for Duchenne cell therapy deramiocelThe U.S. Food and Drug Administration issued a second complete response letter rejecting Capricor Therapeutics' cell therapy deramiocel for Duchenne muscular dystrophy. The agency said the data did…
- RevMed's Rasonque shows strong first-line response and survival benefit in early pancreatic cancer dataRevMed reported early-stage results from its open‑label Phase 1/2 RMC‑GI‑102 trial, presented at the EORTC‑N conference, evaluating Rasonque combined with chemotherapy in patients with first‑line m…